Article
Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
The Journal of molecular diagnostics : JMD - 1 Nov 2022
Jatkoe Timothy, Wang Songbai, Odegaard Justin I, Velasco Roth Anne Marie, Osgood Drew, Martinez Gabriela, Lucas Paul, Curtin Joshua C, Karkera Jayaprakash
Abstract excerpt
Amivantamab, an epidermal growth factor receptor (EGFR)-c-Met bispecific antibody, targets activating/resistance EGFR mutations and MET mutations/amplifications. In the ongoing CHRYSALIS study (ClinicalTrials.gov Identifier: NCT02609776), amivantamab demonstrated antitumor activity in patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations (ex20ins) that progressed on or after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.